Regeneron (REGN) Tops Q4 EPS by 1c

February 9, 2017 6:31 AM EST

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.

Regeneron (NASDAQ: REGN) reported Q4 EPS of $3.04, $0.01 better than the analyst estimate of $3.03. Revenue for the quarter came in at $1.23 billion versus the consensus estimate of $1.3 billion.

"The hard work of our scientists over the last decades has brought Regeneron to the next phase of our evolution - this year we anticipate launching two additional important therapies, significantly expanding our impact for patients with serious diseases and our company\'s growth potential," said Leonard S. Schleifer, M.D., Ph.D., President and Chief Executive Officer of Regeneron. "In March, we look forward to the potential U.S. approval of Dupixent, our innovative and breakthrough IL4/13 blocking antibody, in adults with atopic dermatitis. We believe Dupixent may have the potential to help additional patients with serious allergic diseases, with pivotal Phase 3 data in adult asthma patients expected later this year. We are also studying Dupixent in patients with nasal polyps and pediatric patients with asthma or atopic dermatitis."


EYLEA U.S. net product sales

Single digit percentage growth over 2016

Sanofi reimbursement of Regeneron commercialization-related expenses

$400 million - $450 million

Non-GAAP unreimbursed R&D(2) (4)

$950 million - $1.025 billion

Non-GAAP SG&A(2) (4)

$1.175 billion - $1.250 billion

Effective tax rate

Capital expenditures

$375 million - $450 million

For earnings history and earnings-related data on Regeneron (REGN) click here.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Earnings, Guidance

Related Entities